Revolutionizing neuropsychiatric treatment by precisely targeting the brain circuits underlying symptoms
Our mission
Starting with treatment-resistant addiction
40.3 million people in the US currently suffer from addiction, making substance use disorder a massive public health crisis. Current therapeutics for addiction have high relapse rates (72-88% for opioid use disorder.) Chronic cravings that persist long into sobriety are the largest driver of relapse, necessitating a therapy that can reduce chronic cravings at or before their onset.
At StriaPlex Therapeutics, we are developing a therapy that reduces cravings in individuals with substance use disorder by selectively modulating the hyperactive neural circuits underlying craving and relapse. Our therapy is spatially and temporally precise, meaning it can be used to rapidly mitigate cravings at their exact onset with high efficiency and low side effects.
Our founding team
150+
Trusted Experts
Join Us
Martin Wienisch, PhD
Kian Caplan, PhD Candidate
Cellular and molecular neuroscientist, focused on genetics, epigenetics, and tool development.
Systems and cellular-molecular neuroscientist, focused on disorder pathophysiology and tool development.
Scientific Advisory Board
Fan Wang, PhD
Qian Huang, PhD
Joshua Aronson, MD
James Zhou, MD
Professor of Neuroscience
20+ years experience studying the neurobiological basis of pain and addiction
Biopharmaceutical Executive
20+ years of experience discovering transformative
therapies to treat a wide range of diseases
Attending neurosurgeon at Beth Israel
Specializing in stereotactic and functional surgery with extensive industry collaboration experience
Attending Internist at Mass General hospital
Specializing in treating patients with substance abuse disorder